Shukra Pharmaceuticals proposes preferential share issue to promoters

Shukra Pharmaceuticals Limited is set to hold an extra-ordinary general meeting (EOGM) on Saturday, November 01, 2025, at 11:30 A.M. (IST) via video conferencing to approve the issuance of 46,43,000 convertible equity warrants on a preferential basis to its promoters. The warrants, each convertible into one fully paid-up equity share, will be issued at a price of INR 34/- (including a premium of INR 33/-) per warrant, aggregating to a total issue size of INR 15,78,62,000/-.

The proceeds from this preferential issue are intended for specific purposes, including meeting the company's working capital requirements (INR 9.00 cr), investing in the capital expenditure of subsidiary companies (INR 6.70 cr), and general corporate purposes (INR 0.0862 cr). The "relevant date" for calculating the floor price of the equity shares, pursuant to ICDR Regulations, is Wednesday, October 01, 2025.

The proposed allottees include Anar Jayeshbhai Patel, Dakshesh Rameshchandra Shah, Anar Project Private Limited, Parshva Texchem India Private Limited, and Navkar Surgical Gujarat Limited. The issue is subject to a lock-in period, with equity shares allotted on a preferential basis to promoters and promoter group locked in for eighteen months from the trading approval date, and existing pre-preferential shareholding locked in for 90 trading days from trading approval.